Literature DB >> 34996098

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

Jonathan Tschopp1, Anne Sophie Brunel1, Olivier Spertini2, Anthony Croxatto3, Frederic Lamoth1,4, Pierre Yves Bochud1.   

Abstract

Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  false-positive; intravenous immunoglobulines; onco-hematology; therapeutic antibodies; β-D-glucan

Mesh：

Substances：

Year:  2022        PMID： 34996098     DOI： 10.1093/cid/ciab1028

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  1 in total

1.  The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients.

Authors:  Mohanad M Al-Obaidi; Parham Ayazi; Aishan Shi; Matthew Campanella; Elizabeth Connick; Tirdad T Zangeneh
Journal:  J Fungi (Basel)       Date:  2022-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.